Who
Igor Bilinsky
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Iovance Biotherapeutics; Chief Business Officer, Oncternal Therapeutics; Chief Operating Officer, Armata Pharmaceuticals; GM, Immuno-Oncology/SVP Sp Ops, Ignyta; Sr VP, Corporate Development, Vical.
In numbers
- Trades disclosed
- 141
- Buys
- 1
- Sells
- 7
- Bought
- $128K
- Sold
- $24K
- Companies
- 5
- Companies where not an officer
- 0
- First trade
- 7 Jan 2014
- Last trade
- 8 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 10 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $35K3,976 at $8.70 | filing |
| 8 Sep 2026filed 10 Sep 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $35K3,976 at $8.70 | filing |
| 1 Sep 2026filed 3 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —8,789 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $37K4,472 at $8.28 | filing |
| 1 Sep 2026filed 3 Sep 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,789 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,789 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —8,789 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $37K4,472 at $8.28 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $17K3,976 at $4.23 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —7,813 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $17K3,976 at $4.23 | filing |
| 1 Jun 2026filed 3 Jun 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —8,790 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $18K4,473 at $3.96 | filing |
News
No headline names them, or the companies they trade most, lately.